212 related articles for article (PubMed ID: 32814440)
1. Platelet Dysfunction and Thrombosis in JAK2
Matsuura S; Thompson CR; Belghasem ME; Bekendam RH; Piasecki A; Leiva O; Ray A; Italiano J; Yang M; Merill-Skoloff G; Chitalia VC; Flaumenhaft R; Ravid K
Arterioscler Thromb Vasc Biol; 2020 Oct; 40(10):e262-e272. PubMed ID: 32814440
[TBL] [Abstract][Full Text] [Related]
2. Impact of the serum- and glucocorticoid-inducible kinase 1 on platelet dense granule biogenesis and secretion.
Walker B; Schmid E; Russo A; Schmidt EM; Burk O; Münzer P; Velic A; Macek B; Schaller M; Schwab M; Seabra MC; Gawaz M; Lang F; Borst O
J Thromb Haemost; 2015 Jul; 13(7):1325-34. PubMed ID: 25944668
[TBL] [Abstract][Full Text] [Related]
3. Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm.
Lamrani L; Lacout C; Ollivier V; Denis CV; Gardiner E; Ho Tin Noe B; Vainchenker W; Villeval JL; Jandrot-Perrus M
Blood; 2014 Aug; 124(7):1136-45. PubMed ID: 24951423
[TBL] [Abstract][Full Text] [Related]
4. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
5. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
Rozovski U; Verstovsek S; Manshouri T; Dembitz V; Bozinovic K; Newberry K; Zhang Y; Bove JE; Pierce S; Kantarjian H; Estrov Z
Haematologica; 2017 Jan; 102(1):79-84. PubMed ID: 27686378
[TBL] [Abstract][Full Text] [Related]
6. Essential thrombocythaemia with mutation in
Alvarez-Larran A; Martínez D; Arenillas L; Rubio A; Arellano-Rodrigo E; Hernández Boluda JC; Papaleo N; Caballero G; Martínez C; Ferrer-Marín F; Mata MI; Pérez-Encinas M; Durán MA; Alonso JM; Carreño-Tarragona G; Alonso JM; Noya S; Magro E; Pérez R; López-Guerra M; Pastor-Galán I; Cervantes F; Besses C; Colomo L; Rozman M
J Clin Pathol; 2018 Nov; 71(11):975-980. PubMed ID: 29934356
[TBL] [Abstract][Full Text] [Related]
7. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
8. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
9. Effect of CALR and JAK2 mutations on the clinical and hematological phenotypes of the disease in patients with myelofibrosis - long-term experience from a single center.
Palova M; Szotkowski T; Hlusi A; Indrak K; Navratilova J; Divoka M; Papajik T
Neoplasma; 2018; 65(2):296-303. PubMed ID: 29534592
[TBL] [Abstract][Full Text] [Related]
10. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.
Toyama K; Karasawa M; Yamane A; Irisawa H; Yokohama A; Saitoh T; Handa H; Matsushima T; Sawamura M; Miyawaki S; Murakami H; Nojima Y; Tsukamoto N
Br J Haematol; 2007 Oct; 139(1):64-9. PubMed ID: 17854308
[TBL] [Abstract][Full Text] [Related]
11. Kinesin-1 Is a New Actor Involved in Platelet Secretion and Thrombus Stability.
Adam F; Kauskot A; Kurowska M; Goudin N; Munoz I; Bordet JC; Huang JD; Bryckaert M; Fischer A; Borgel D; de Saint Basile G; Christophe OD; Ménasché G
Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1037-1051. PubMed ID: 29519941
[TBL] [Abstract][Full Text] [Related]
12. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of CALR, JAK2 and MPL gene mutations in BCR-ABL negative myeloproliferative neoplasms].
Ouyang Y; Qiao C; Wang J; Xiao L; Zhang S
Zhonghua Yi Xue Za Zhi; 2015 May; 95(18):1369-73. PubMed ID: 26178351
[TBL] [Abstract][Full Text] [Related]
14. Platelets from Calreticulin mutated essential thrombocythemia patients are less reactive than JAK2 V617F mutated platelets.
Hauschner H; Bokstad Horev M; Misgav M; Nagar M; Seligsohn U; Rosenberg N; Koren-Michowitz M
Am J Hematol; 2020 Apr; 95(4):379-386. PubMed ID: 31868244
[TBL] [Abstract][Full Text] [Related]
15. The Role of Megakaryocytes in Myelofibrosis.
Melo-Cardenas J; Migliaccio AR; Crispino JD
Hematol Oncol Clin North Am; 2021 Apr; 35(2):191-203. PubMed ID: 33641863
[TBL] [Abstract][Full Text] [Related]
16. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
17. Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis.
Alvarez-Larrán A; Arellano-Rodrigo E; Reverter JC; Domingo A; Villamor N; Colomer D; Cervantes F
Ann Hematol; 2008 Apr; 87(4):269-76. PubMed ID: 17899078
[TBL] [Abstract][Full Text] [Related]
18. The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis.
Kirabo A; Park SO; Wamsley HL; Gali M; Baskin R; Reinhard MK; Zhao ZJ; Bisht KS; Keserű GM; Cogle CR; Sayeski PP
Am J Pathol; 2012 Sep; 181(3):858-65. PubMed ID: 22796437
[TBL] [Abstract][Full Text] [Related]
19. Frequency and molecular characteristics of calreticulin gene (CALR) mutations in patients with JAK2 -negative myeloproliferative neoplasms.
Wojtaszewska M; Iwoła M; Lewandowski K
Acta Haematol; 2015; 133(2):193-8. PubMed ID: 25323779
[TBL] [Abstract][Full Text] [Related]
20. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.
Tiedt R; Hao-Shen H; Sobas MA; Looser R; Dirnhofer S; Schwaller J; Skoda RC
Blood; 2008 Apr; 111(8):3931-40. PubMed ID: 18160670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]